APKN Airprotek International Inc. Corp.

Rafarma Joins with Glorija Kotnik to New Victories

Rafarma Joins with Glorija Kotnik to New Victories

RAFARMA PHARMACEUTICALS INC. “OTC:(RAFA)”

Ljubljana, Slovenia , May 30, 2019 (GLOBE NEWSWIRE) -- Rafarma (OTC: RAFA), a Wyoming Corporation, has hired internationally acclaimed professional snowboarder Glorija Kotnik as its spokesperson and new face of the company. The pairing launches a joint campaign “Together to New Victories” for Rafarma and Ms. Kotnik in the pursuit of peak human performance.

Ms. Kotnik is a member of the Slovenian National Snowboard Team and three-time Olympian (2010 Vancouver, 2014 Sochi and 2018 PyeongChang). With more than 120 International Ski Federation (FIS) races under her belt, she will forever be one of, if not the best, Slovenian female snowboarders of all time.

“I am very excited to be the new face of Rafarma Pharmaceuticals. I believe the company’s high-quality natural products manufactured in Slovenia will meet the great demand around the world for natural, performance-improving supplements. I am also pleased to see the company moving forward with the introduction of new products, some of which will be based on cannabis infusion. Although my winter season has just finished, preparations for next season will soon begin. Using Rafarma products, I believe I will see even better performance results next season. Together with Rafarma to New Victories!” - stated Ms. Kotnik.

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For more information contact:

RAFARMA

307-920-0161

Attachments

EN
30/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Airprotek International Inc. Corp.

 PRESS RELEASE

Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceuti...

Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University Wyoming, USA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences (Pvt) Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023. It is Sri Lanka's first and only pharmaceutical manufacturing facility for sterile liquid injections and infusions. The headquarters of the company is based in Kandy...

 PRESS RELEASE

Rafarma Pharmaceutical news update

Rafarma Pharmaceutical news update Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards. Due to the changed geopolitical situation, the company was unable to complete the review of some of the assets that were set for audit consolidation, namely Kraspharma and Bebig. The Company will continue to provide its shareholders with regular unaudited financial statements of Kraspharma and Bebig. Onc...

 PRESS RELEASE

Rafarma Pharmaceuticals strengthens its position in Central Asia

Rafarma Pharmaceuticals strengthens its position in Central Asia Nicosia, Cyprus, April 29, 2022 (GLOBE NEWSWIRE) -- Representatives of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) visited Uzbekistan and discussed the prospects for the company's development in the territory of the innovative research and production pharmaceutical cluster "Tashkent Pharma Park". Rafarma Pharmaceuticals is not new to the Central Asian market, the company has been operating there for a long time and plans to increase its presence by creating local production. Over the next three years, the company plans to bui...

 PRESS RELEASE

Rafarma’s Slavich Noya Technology Division Expands Printing Production

Rafarma’s Slavich Noya Technology Division Expands Printing Production Nicosia, Cyprus, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) Slavich Noya Technology, part of the Rafarma Pharmaceuticals group of companies, is expanding its production capabilities as it is in active negotiations for the acquisition of two machines from BOBST (), one of the world’s leading suppliers of substrate processing, printing and converting equipment and services for the label, flexible packaging, folding carton and corrugated board industries. Slavich Noya Technology will great...

 PRESS RELEASE

RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear...

RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear Research Nicosia, Cyprus, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is currently negotiating with the Joint Institute for Nuclear Research (JINR), an international intergovernmental scientific organization established by eleven founding countries in 1956 and registered by the United Nations. The purpose of the current negotiations is the development and implementation of Rafarma Pharmaceuticals’ projects related to nuclear medicine technologies, radiopharmaceuticals, radiotherapy and pr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch